期刊
JOURNAL OF CLINICAL IMMUNOLOGY
卷 36, 期 -, 页码 S100-S107出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-016-0265-6
关键词
Antibody drug conjugates(ADCs); drug-antibody ratio (DAR); site-specific conjugation; therapeutic window; unnatural amino acids (UAA); monomethyl auristatin E/F (MMAE/MMAF); THIOMAB; microbial transglutaminase (MTG); formylglycine generating enzyme(FGE); Sortase A; tubulin tyrosine ligase (TTL); Tub-tag
类别
资金
- Deutsche Forschungsgemeinschaft [SPP1623, HA 4468/9-1, LE 721/13-1]
- Fonds der Chemischen Industrie (FCI)
Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals, combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs on the market, a plethora of novel ADC technologies has emerged, covering as diverse aspects as antibody engineering, chemical linker optimization and novel conjugation strategies, together aiming at constantly widening the therapeutic window for ADCs. This review primarily focuses on novel chemical and biotechnological strategies for the site-directed attachment of drugs that are currently validated for 2nd generation ADCs to promote conjugate homogeneity and overall stability.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据